Ceek.jp Altmetrics (α ver.)
  1. ホーム
  2. 文献一覧: Satoshi Akagi (著者)
  3. 2件

1 0 0 0 OA Overview of the 86th Annual Scientific Meeting of the Japanese Circulation Society ― Cardiology Spreading Its Wings ―

著者
Kazufumi Nakamura Toru Miyoshi Satoshi Akagi Norihisa Toh Yukihiro Saito Yoichi Takaya Masatoki Yoshida Koji Nakagawa Satoshi Kawada Hironobu Toda Takashi Miki Rie Nakayama Fumi Yokohama Keishi Ichikawa Masashi Yoshida Makiko Taniyama Nobuhiro Nishii Teiji Akagi Hiroshi Morita Hiroshi Ito
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
pp.CJ-22-0349, (Released:2022-06-29)
参考文献数
3
被引用文献数
1
The 86thAnnual Scientific Meeting of the Japanese Circulation Society was held in a web-based format on March 11–13, 2022. In accordance with the internationalization policy of the JCS, the meeting was held with the Asian Pacific Society of Cardiology Congress 2022. The main theme was “Cardiology Spreading its Wings”. The number of patients with heart failure and other cardiovascular diseases is increasing dramatically, and the fields dealt with by cardiovascular medicine are also greatly expanding. This conference was both intellectually satisfying and exciting for all participants, who numbered over 14,900. The meeting was completed with great success, and the enormous amount of cooperation and support from all involved was greatly appreciated.

1 0 0 0 OA Treat and Repair Strategy in Patients With Atrial Septal Defect and Significant Pulmonary Arterial Hypertension

著者
Yasufumi Kijima Teiji Akagi Yoichi Takaya Satoshi Akagi Koji Nakagawa Kengo Kusano Shunji Sano Hiroshi Ito
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
vol.80, no.1, pp.227-234, 2015-12-25 (Released:2015-12-25)
参考文献数
29
被引用文献数
8 35
Background:A therapeutic strategy in patients with atrial septal defect (ASD) and significant pulmonary arterial hypertension (PAH) remains controversial. This study aimed to assess the effect of PAH-specific medications and subsequent transcatheter shunt closure (ie, a treat and repair strategy) in these patients.Methods and Results:Among 646 patients with ASD, 22 patients (mean age of 56±20 years) who had PAH [mean pulmonary artery pressure ≥25 mmHg and pulmonary vascular resistance (PVR) ≥3 Wood units] underwent successful transcatheter ASD closure. Prior to the procedure, 8 patients received PAH-specific medications (PHM group) and 14 patients did not (non-PHM group). Initially, the PHM group had higher PVR compared with non-PHM group (9.6±3.8 vs. 4.2±1.0 Wood units, P<0.01). After treatment with PAH-specific medications, PVR in this group decreased to 4.0±0.8 Wood units (P<0.01). No adverse events were observed in either the PHM or non-PHM group during or after the transcatheter procedure. In the PHM group, during a treatment period of 52±48 months, the World Health Organization Functional Classification significantly improved (3.0±0.5 to 2.0±0.0, P<0.01), as well as in the non-PHM group (2.1±0.6 to 1.5±0.5, P<0.01).Conclusions:Treat and repair strategy provided substantial improvement and no worsening of the WHO-FC, even in patients with ASD and significant PAH. Long-term hemodynamic follow-up is mandatory to evaluate the ultimate efficacy and safety of this new strategy. (Circ J 2016; 80: 227–234)